FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387402138> ?p ?o ?g. }

• W4387402138 endingPage "101681" @default.
• W4387402138 startingPage "101681" @default.
• W4387402138 abstract "Metastatic colorectal cancer (mCRC) is the 2nd leading cause of cancer deaths in the US. >50% of patients with mCRC harbor mutations in KRAS or NRAS. Direct RAS targeting has failed to benefit patients with mCRC. Targeting MEK, a downstream mediator of RAS, failed to demonstrate efficacy in patients with mCRC. We hypothesize that identifying combination therapies using unbiased screening has the potential to improve the efficacy of MEK targeting in patients with KRAS mutated mCRC. The aims of this study were to perform unbiased high-throughput screening (HTS) using KRAS mutated CRC spheroids to identify drugs that, when combined with the MEK inhibitor trametinib, would enhance its efficacy. We performed unbiased HTS using KRAS mutated CRC spheroids to investigate the synergistic effect of trametinib with agents from two distinct “clinically ready” compound library sets: 1) the NCI oncology set V, and 2) a custom compound set composed of FDA approved drugs or drugs in clinical trials. Using the Bliss model of synergy, paclitaxel was identified to be synergistic with trametinib. Effects of combining trametinib with paclitaxel were validated in vitro by cell growth assays and in vivo using KRAS mutated patient derived xenografts (PDXs). HTS studies showed that combining trametinib with paclitaxel was synergistic in CRC spheroids. This combination was validated in vitro by MTT and colony formation assays in multiple CRC cell lines. Analyses of Annexin V/PI staining by flow cytometry demonstrated that the drug combination increased cell death in multiple CRC cell lines when compared to single agents. Importantly, when compared to the monotherapies, combining trametinib with paclitaxel led to significant tumor growth inhibition in PDXs with KRAS G12D and G13D mutations, but not in a PDX with KRAS G12C mutation. Our unbiased HTS and in vitro and in vivo validation studies demonstrated that combining trametinib with paclitaxel can enhance the efficacy of MEK inhibitors in KRAS mutated CRC cells and PDXs. Our in vivo studies using clinically achievable doses may serve as the basis for future clinical studies to determine the efficacy of this drug combination in patients with KRAS mutated mCRC." @default.
• W4387402138 created "2023-10-07" @default.
• W4387402138 creator A5006530291 @default.
• W4387402138 creator A5028702533 @default.
• W4387402138 creator A5030825527 @default.
• W4387402138 creator A5042341684 @default.
• W4387402138 creator A5063114221 @default.
• W4387402138 creator A5079659253 @default.
• W4387402138 creator A5084099617 @default.
• W4387402138 date "2023-10-01" @default.
• W4387402138 modified "2023-10-07" @default.
• W4387402138 title "35P Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells" @default.
• W4387402138 doi "https://doi.org/10.1016/j.esmoop.2023.101681" @default.
• W4387402138 hasPublicationYear "2023" @default.
• W4387402138 type Work @default.
• W4387402138 citedByCount "0" @default.
• W4387402138 crossrefType "journal-article" @default.
• W4387402138 hasAuthorship W4387402138A5006530291 @default.
• W4387402138 hasAuthorship W4387402138A5028702533 @default.
• W4387402138 hasAuthorship W4387402138A5030825527 @default.
• W4387402138 hasAuthorship W4387402138A5042341684 @default.
• W4387402138 hasAuthorship W4387402138A5063114221 @default.
• W4387402138 hasAuthorship W4387402138A5079659253 @default.
• W4387402138 hasAuthorship W4387402138A5084099617 @default.
• W4387402138 hasBestOaLocation W43874021381 @default.
• W4387402138 hasConcept C121608353 @default.
• W4387402138 hasConcept C126322002 @default.
• W4387402138 hasConcept C143998085 @default.
• W4387402138 hasConcept C184235292 @default.
• W4387402138 hasConcept C21790070 @default.
• W4387402138 hasConcept C2777292972 @default.
• W4387402138 hasConcept C2778472372 @default.
• W4387402138 hasConcept C2781187634 @default.
• W4387402138 hasConcept C2781249067 @default.
• W4387402138 hasConcept C502942594 @default.
• W4387402138 hasConcept C526805850 @default.
• W4387402138 hasConcept C57074206 @default.
• W4387402138 hasConcept C71924100 @default.
• W4387402138 hasConcept C86803240 @default.
• W4387402138 hasConcept C95444343 @default.
• W4387402138 hasConceptScore W4387402138C121608353 @default.
• W4387402138 hasConceptScore W4387402138C126322002 @default.
• W4387402138 hasConceptScore W4387402138C143998085 @default.
• W4387402138 hasConceptScore W4387402138C184235292 @default.
• W4387402138 hasConceptScore W4387402138C21790070 @default.
• W4387402138 hasConceptScore W4387402138C2777292972 @default.
• W4387402138 hasConceptScore W4387402138C2778472372 @default.
• W4387402138 hasConceptScore W4387402138C2781187634 @default.
• W4387402138 hasConceptScore W4387402138C2781249067 @default.
• W4387402138 hasConceptScore W4387402138C502942594 @default.
• W4387402138 hasConceptScore W4387402138C526805850 @default.
• W4387402138 hasConceptScore W4387402138C57074206 @default.
• W4387402138 hasConceptScore W4387402138C71924100 @default.
• W4387402138 hasConceptScore W4387402138C86803240 @default.
• W4387402138 hasConceptScore W4387402138C95444343 @default.
• W4387402138 hasIssue "1" @default.
• W4387402138 hasLocation W43874021381 @default.
• W4387402138 hasOpenAccess W4387402138 @default.
• W4387402138 hasPrimaryLocation W43874021381 @default.
• W4387402138 hasRelatedWork W2029503777 @default.
• W4387402138 hasRelatedWork W2041488531 @default.
• W4387402138 hasRelatedWork W2125845533 @default.
• W4387402138 hasRelatedWork W2266896604 @default.
• W4387402138 hasRelatedWork W2315043173 @default.
• W4387402138 hasRelatedWork W2603968999 @default.
• W4387402138 hasRelatedWork W2730247823 @default.
• W4387402138 hasRelatedWork W2885442085 @default.
• W4387402138 hasRelatedWork W2997573493 @default.
• W4387402138 hasRelatedWork W4242147590 @default.
• W4387402138 hasVolume "8" @default.
• W4387402138 isParatext "false" @default.
• W4387402138 isRetracted "false" @default.
• W4387402138 workType "article" @default.